profit from every $100 of sales.
$0$100
Halozyme Therapeutics
$100.27-0.40% today
+40.8% in 1 year
1-year low $61.631-year high $131.18
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $36.08 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Halozyme Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $660 million in 2022 to $1.40 billion in 2025, with $317 million of profit last year.
SalesProfit
Halozyme Therapeutics handed back 96% of the cash it generated last year.
Buybacks $342M
Free cash flow 2025$357M
Bought back its own shares$342M
Paid as dividends–
Cash vs. debt$134M vs. $2.1B
Halozyme Therapeutics vs. similar companies
Halozyme Therapeutics grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Halozyme Therapeutics | 36.1× · Expensive | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Halozyme Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 268 | 443 | 660 | 829 | 1,015 | 1,397 | |
| 224 | 362 | 521 | 637 | 856 | 1,168 | |
| 144 | 276 | 268 | 338 | 551 | 803 | |
| 153 | 259 | 316 | 452 | 657 | 573 | |
| 129 | 403 | 202 | 282 | 444 | 317 | |
| 0.91 | 2.74 | 1.44 | 2.10 | 3.43 | 2.56 | |
| 83.8% | 81.6% | 78.9% | 76.8% | 84.3% | 83.6% | |
| 53.9% | 62.2% | 40.5% | 40.7% | 54.3% | 57.5% | |
| 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 580 | 1,104 | 1,842 | 1,733 | 2,063 | 2,525 |
| Cash | 148 | 119 | 234 | 118 | 116 | 134 |
| Total debt | 0 | 787 | 1,506 | 1,499 | 1,506 | 2,143 |
| Total liabilities | – | – | 1,672 | 1,649 | 1,700 | 2,477 |
| 151 | 197 | 170 | 84 | 364 | 49 | |
| 141 | 147 | 141 | 134 | 129 | 124 | |
| 78.3% | 20.6% | 12.5% | 18.3% | 24.3% | 17.5% | |
| 85.5% | 204.5% | 119.0% | 336.0% | 122.1% | 649.2% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 55 | 299 | 240 | 389 | 479 | 652 | |
| 3 | 1 | 5 | 15 | 11 | 295 | |
| 53 | 298 | 235 | 373 | 468 | 357 | |
| Dividends paid | – | – | – | – | – | – |
| 150 | 350 | 200 | 402 | 250 | 342 | |
| 17 | 21 | 24 | 37 | 43 | 52 |
Valuation
- 36.1×
- 12.4×
- 1.57
- 37.0×
- 8.2×
- 32.0×
- 23.5×
- 3.1%
- 2.8%
- 0.0%
Profitability
- 83.6%
- 57.5%
- 22.7%
- 63.7%
- 23.6%
- 21.1%
- 126.3%
- 13.1%
- 37.2%
- 6.1%
Growth
- +39.2%
- +23.0%
- +37.6%
- –
- −3.9%
Financial health
- 1.9×
- 9.76
- 80.2%
- 45.0×
- 2.76
- 2.33
- 0.56
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 6%of 963
Top 1%of 894
Bottom 36%of 632
Top 14%of 908
Top 36%of 991
What analysts expect
- Average price target
- $75.60
- Range
- $56.00 – $96.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | 1.60 | 1.54 | +3.9% |
| Feb 17, 2026 | -0.24 | 2.15 | −111.2% |
| Nov 3, 2025 | 1.72 | 1.63 | +5.5% |
| Aug 5, 2025 | 1.54 | 1.23 | +25.2% |
| May 6, 2025 | 1.11 | 0.95 | +16.8% |
| Feb 18, 2025 | 1.26 | 1.17 | +7.7% |
| Oct 31, 2024 | 1.27 | 0.98 | +29.6% |
| Aug 6, 2024 | 0.91 | 0.76 | +19.7% |
News
Strong Royalties and New Launches Accelerate Halozyme Therapeutics’ (HALO) Growth MomentumYahoo Finance · Oct 27, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
5/7Passes 5 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
75Pass
Benjamin Graham
41No pass
Philip Fisher
88Pass
Peter Lynch
76Pass
Joel Greenblatt
32No pass
Charlie Munger
85Pass
Terry Smith
89Pass
Questions about Halozyme Therapeutics
Is Halozyme Therapeutics a good stock to buy?
A strong, very profitable business, but the price is high. 5 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Halozyme Therapeutics AI analysis
What does Halozyme Therapeutics do?
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. It is in Biotechnology, based in San Diego, CA, United States, with 423 employees.
Does Halozyme Therapeutics pay a dividend?
No. Halozyme Therapeutics does not pay a dividend at the moment; in 2025 it returned $342 million to shareholders by buying back its own shares.
Is Halozyme Therapeutics stock halal?
Yes. Halozyme Therapeutics passes our halal screen: its business is permitted and its debt is 19% of its market value, under the 30% limit. How we check
How has Halozyme Therapeutics stock done over the past year?
Up 40.8% over the past twelve months, to $100.27. It traded between $61.63 and $131.18 and is 23.6% below its high.
Who are Halozyme Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Halozyme Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.